A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Pfizer
Tesaro, Inc.
Shanghai Junshi Bioscience Co., Ltd.
NSABP Foundation Inc
Gilead Sciences
Eli Lilly and Company
Wake Forest University Health Sciences
Masonic Cancer Center, University of Minnesota
University of Arizona
University of Arizona